Skip to content
Viraday

Viraday

Emtricitabine · Tenofovir Disoproxil · Efavirenz

Efavirenz, emtricitabine and tenofovir tablets for HIV-1 infection. Combining three antiretrovirals lowers the chance of resistance.

All strengths and pack prices
StrengthPackPricePer unit
1.1gm30 tablets$87.00$2.90
1.1gm60 tablets$173.00$2.88
1.1gm90 tablets$256.00$2.84
Route
Oral use
Form
Tablet
Strengths
1.1gm

Viraday details

Alternative names
emtricitabine, tenofovir, efavirenz
Therapeutic class
Nucleoside Analog and Non-Nucleoside Reverse Transcriptase Inhibitor Combination
Pharmacological class
Antiretroviral Combination
Minor side effects
dizziness; headache; insomnia
Moderate side effects
vivid dreams; rash; diarrhoea
Dosage forms
Tablet
Administration route
Oral use
Manufacturer
Cipla Ltd
Onset time
2–4 weeks
Duration
24 hours
Storage instructions
Store below 25°C.
Drug interactions
Rifampin; Simvastatin; St. John's Wort
Age restrictions
Approved for adults weighing over forty kilograms.
Contraindications

severe renal impairment; concurrent highly CYP3A4-dependent therapies; hepatic failure

Serious side effects

lactic acidosis, requires immediate medical attention; severe hepatotoxicity, requires immediate medical attention; suicidal ideation, requires immediate medical attention

Patient summary

Efavirenz, emtricitabine and tenofovir tablets for HIV-1 infection. Combining three antiretrovirals lowers the chance of resistance.

Mechanism of action

Combines emtricitabine and tenofovir to terminate the viral DNA chain with efavirenz to inhibit reverse transcriptase non-competitively.

Pregnancy and breastfeeding

Pregnancy: Avoid in first trimester. Discontinue breastfeeding to prevent transmission. Breastfeeding: Confirm breastfeeding suitability with a qualified clinician or pharmacist before use.